Sourcing Aged Care Equipment from China: A Complete Guide for Australian Providers

The Aged Care Equipment Funding Challenge in Australia

Australian aged care providers are navigating a structural cost crisis. Government expenditure on residential aged care reached $24 billion in FY2024-25, a 12.8% increase from the prior year, driven by higher AN-ACC funding, increased mandatory care minutes and workforce wage uplifts. Yet for most providers, the funding increases have not kept pace with the full cost of delivering compliant, high-quality care. Equipment procurement sits at the centre of this tension.

The introduction of the new Aged Care Act and its associated service list has expanded mandatory equipment requirements for residential facilities. Recliner chairs, adjustable beds, pressure care systems and assistive technology that were previously discretionary investments have become baseline obligations. At the same time, capital subsidy funding remains insufficient for the refurbishment and fit-out work required to meet contemporary standards, with the industry estimating capital needs over the next decade exceeding $55 billion.

For home-based aged care providers, the November 2025 launch of the Support at Home Program (replacing Home Care Packages) introduced an eight-level funding structure with quarterly budgets ranging from $2,674 to $19,427 per participant. Separately, the Assistive Technology and Home Modifications (AT-HM) scheme provides up to $15,000 (or more where clinically justified) for mobility aids, communication devices, continence equipment and other supportive technologies. These funding streams have increased the total equipment budget available per care recipient but have also intensified scrutiny of cost-effectiveness: the NDIA and My Aged Care assessors are required to fund the most cost-effective option that meets the participant's assessed needs.

For NDIS participants under 65, the scheme funds assistive technology under Capital Supports with no fixed dollar cap, but requires demonstrated value for money relative to alternatives. With reforms targeting a reduction in average plan spending, the pressure on providers to source compliant equipment at lower cost has never been greater.

The practical result is straightforward: aged care providers who continue to source mobility aids, beds, patient handling equipment and assistive technology exclusively from Australian distributors of European or American brands are carrying a cost premium of 40 to 70% that cannot be justified against equivalent products sourced from verified Chinese manufacturers. For residential facilities managing hundreds of residents and home care organisations supplying equipment to thousands of clients, the compounding cost difference is material.

Why Chinese Manufacturers Are the Answer

China is the world's largest manufacturer of medical rehabilitation equipment, mobility aids and aged care consumables. The country's dominance in these categories is not simply a function of low labour costs. It reflects decades of investment in manufacturing scale, vertical supply chain integration, export certification capability and design refinement driven by enormous domestic and export demand.

Cost Advantage: 40 to 70% Below European and US Pricing

A standard manual wheelchair sourced from a verified Chinese manufacturer and delivered to Australia as a TGA-listed Class I medical device typically costs $180 to $280 landed, compared to $450 to $750 for a European-branded equivalent sold through Australian distributors. A powered electric nursing bed with four-section profiling, pressure-relieving mattress and side rails, ARTG-listed and delivered to a residential facility, typically costs $900 to $1,400 from a Chinese manufacturer compared to $2,200 to $3,800 from European or domestic suppliers. An overhead patient hoist system sourced from a Chinese manufacturer with CE marking and ARTG listing typically arrives at 35 to 50% of the cost charged by the Australian distributor of an equivalent European brand.

These savings are achievable after accounting for sea freight (typically $60 to $150 per item depending on weight and volume), import duties (most aged care equipment attracts 0% under ChAFTA), TGA compliance documentation and pre-shipment inspection costs. The total landed cost remains highly competitive, and for providers purchasing at volume, the savings are compounded across every procurement cycle.

Quality Trajectory: ISO 13485, CE Marking and ARTG-Ready Products

The quality of Chinese aged care and rehabilitation equipment has improved substantially over the past decade. Manufacturers in Guangdong, Jiangsu, Hebei and Shandong provinces now supply European hospitals, NHS trusts and major North American healthcare distributors under their own brands and as OEM manufacturers for established international labels. Many of the branded aged care products sold in Australia through domestic distributors are manufactured in Chinese factories.

Leading Chinese aged care equipment manufacturers hold ISO 13485:2016 quality management certification (the international medical device quality management standard, adopted in Australia as AS ISO 13485:2017), CE marking from European Notified Bodies, and in many cases existing ARTG entries for the Australian market. For categories with existing ARTG listings, the compliance pathway for Australian providers is straightforward. For new products or manufacturers without existing Australian listings, the CE certificate and ISO 13485 certification form the foundation of the TGA ARTG application.

The key distinction from a decade ago is that quality is now verifiable through internationally recognised certification systems rather than estimated. A Chinese factory holding a valid CE certificate issued by a recognised European Notified Body has been audited against the same technical standards as a German or French manufacturer. The TGA accepts this evidence for most device classifications, which fundamentally changes the risk profile of sourcing from China compared to five or ten years ago.

Product Range: Full Coverage of Aged Care Equipment Needs

Chinese manufacturers now cover the full spectrum of aged care equipment required by Australian residential facilities and home care providers. There is no significant product category in the aged care equipment market that cannot be sourced from verified Chinese manufacturers with appropriate export certification. The range extends from basic consumables (continence products, wound care accessories) through to complex assistive technology (powered wheelchairs, fall detection systems, nurse call infrastructure) and large fit-out items (facility furniture, dining equipment, communal area furnishings).

Key Aged Care Product Categories Available from Verified Chinese Manufacturers

Mobility Aids

Mobility aids represent the highest-volume procurement category for most aged care providers, across both residential and home care settings. Chinese manufacturers dominate global production in this category. Standard manual wheelchairs, bariatric wheelchairs, transport chairs, lightweight folding chairs and tilt-in-space manual chairs are all widely available from ISO 13485-certified manufacturers with existing CE marking and ARTG-listed products in the Australian market.

Rollators (three-wheel and four-wheel walkers with brakes and seats), standard aluminium walkers, forearm crutches and quad canes are classified as Class I medical devices in Australia and have the simplest ARTG pathway. Powered mobility scooters (Class I or IIa depending on configuration) and powered wheelchairs (Class IIa) are also widely manufactured in China, with Guangdong-based manufacturers such as those in Foshan and Shunde having extensive export experience and ARTG-listed products already available in Australia.

Patient Handling: Hoists, Slings, Transfer Aids and Shower Chairs

Patient handling equipment is a high-value, safety-critical category where TGA compliance is non-negotiable. Overhead ceiling track hoist systems, portable floor hoists (passive and active), hoist slings in a range of configurations (universal, hammock, divided leg, amputee), transfer boards, gait belts and standing aids are all available from Chinese manufacturers with CE marking and ISO 13485 certification. Shower chairs, commode chairs, toilet safety frames and bath lifts, used extensively across both residential and home care settings, are largely Class I devices with straightforward ARTG pathways.

The cost advantage in patient handling equipment is particularly significant. A portable floor hoist from a verified Chinese manufacturer with CE marking typically costs $600 to $1,100 landed in Australia, compared to $2,000 to $3,500 for equivalent European-branded products through Australian distributors. For residential facilities investing in ceiling track systems across resident rooms, the per-track-system cost saving can represent $1,500 to $4,000 per room when sourcing directly from China.

Beds and Pressure Care

Electric nursing beds are a high-cost capital item for residential aged care facilities. Chinese manufacturers produce a comprehensive range, from basic two-section electric beds to fully-profiling four-section nursing beds with integrated weighing scales, CPR-release mechanisms, low-height positioning to 25cm, side rails with integrated call systems, and compatible pressure care surfaces. For palliative care settings, Chinese manufacturers also produce profiling beds with specific features for comfort care, including ultra-low height, full lateral tilt and integrated mattress retainers for specialised pressure care surfaces.

Pressure care products, including viscoelastic foam mattresses, alternating pressure overlay and replacement systems, foam positioning wedges and heel protectors, are produced at substantial scale by Chinese manufacturers with CE marking. These products sit at the intersection of the TGA medical device framework and the significant clinical risk associated with pressure injury in aged care, making compliance documentation essential. Reputable Chinese manufacturers in this category produce clinical evaluation reports, post-market surveillance data and risk management documentation consistent with TGA Essential Principles requirements.

Continence Products and Consumables

Continence products represent the largest ongoing consumable spend for most residential aged care facilities. Adult absorbent products, underpads, continence pads, penile sheaths, indwelling catheter supplies and associated accessories are produced at enormous scale by Chinese manufacturers, with consistent quality and strong CE and ISO certification backgrounds. These products are typically Class I or Class IIa medical devices under TGA classification, with relatively straightforward ARTG inclusion processes for sponsors with appropriate manufacturer documentation.

For providers currently purchasing continence products from Australian distributors of European brands, direct-from-China procurement with appropriate ARTG listing represents some of the most accessible and highest-return cost reduction available. Volume commitments across a residential facility's resident population create predictable demand that Chinese manufacturers can supply on a schedule basis, with pre-shipment inspection and batch testing included in the sourcing process.

Monitoring and Assistive Technology

The monitoring and assistive technology category has seen significant product development from Chinese manufacturers in recent years. Fall detection devices (wearable and room-based), nurse call systems, vital signs monitoring equipment (non-invasive blood pressure monitors, pulse oximeters, temperature monitoring), bed exit sensors, wandering prevention systems and personal emergency response systems are all available from Chinese manufacturers with appropriate CE and ISO 13485 certification.

This category aligns with the AT-HM scheme's funded equipment list, which includes video call systems, personal alarms, fall detectors, blood pressure monitors, telehealth platforms and wearable fitness trackers. For healthcare research and technology applications in aged care, Chinese manufacturers are also producing remote monitoring solutions and integrated sensor platforms that align with Australia's direction toward technology-assisted care under the new Aged Care Act. The TGA classification for monitoring devices ranges from Class I (non-measuring, non-active) to Class IIa (active devices with measuring function), with the appropriate ARTG pathway determined by the specific device's intended purpose and risk class.

Facility Fit-Out: Furniture, Dining and Communal Areas

Beyond medical devices, the mandatory service list for residential aged care now includes specific requirements for facility furniture: recliner chairs, adjustable dining chairs, purpose-designed dining tables, communal lounge furniture appropriate for the resident population's mobility and positioning needs, and outdoor furniture meeting safety and accessibility requirements. These items are not regulated as medical devices but must meet Australian Standards for furniture quality, stability and fire resistance.

Chinese manufacturers produce the full range of aged care facility furniture to specification, with Australian-standard certifications available for materials and fire ratings. The cost saving on furniture procurement from China compared to Australian or European commercial furniture suppliers typically ranges from 35 to 60%, with the added flexibility of customisation in fabric, colour and configuration to meet facility fit-out requirements.

TGA Requirements for Medical Devices in Aged Care

The Therapeutic Goods Administration (TGA) regulates medical devices supplied in Australia under the Therapeutic Goods Act 1989 and the Therapeutic Goods (Medical Devices) Regulations 2002. All medical devices must be included on the Australian Register of Therapeutic Goods (ARTG) before they can be legally supplied to aged care facilities, home care recipients or NDIS participants, unless a specific exemption applies.

Device Classification

TGA medical device classification mirrors the European system, which means Chinese manufacturers targeting the European market are already producing to the same classification standards that apply in Australia. The classification determines the conformity assessment pathway and the level of scrutiny applied to the ARTG application:

• Class I (non-sterile, non-measuring): Lowest risk. Includes most standard manual wheelchairs, walking frames, shower chairs, commode chairs, positioning aids and basic patient handling equipment. Self-declaration by the manufacturer is sufficient; no Notified Body certification is required. ARTG inclusion is based on the manufacturer's Declaration of Conformity and the sponsor's application. These products have the simplest and lowest-cost compliance pathway.
• Class Is / Class Im (sterile or measuring function): Includes devices supplied sterile (such as continence catheters, sterile dressings) or those with a measuring function (such as calibrated blood pressure monitors). Requires a TGA conformity assessment certificate or CE certificate from a Notified Body.
• Class IIa: Low to moderate risk. Includes powered wheelchairs, powered mobility scooters, patient lifts and hoists, electric nursing beds, some fall detection devices and vital signs monitors with active measuring functions. Requires a CE certificate from a European Notified Body or TGA conformity assessment certificate. ISO 13485 certification is a prerequisite for obtaining these certificates.
• Class IIb: Moderate to high risk. Includes active pressure care systems (alternating pressure mattresses with electronic pump units), long-term implantable devices and certain monitoring systems. Requires CE certificate or TGA conformity assessment with higher-level audit requirements.
• Class III: Highest risk. Not typically relevant to standard aged care equipment categories.

What Chinese Suppliers Need to Provide

For ARTG inclusion, the Australian sponsor (importer) must obtain the following documentation from the Chinese manufacturer:

• CE certificate issued by a recognised European Notified Body (accepted by TGA as manufacturer evidence for most Class I through IIb devices)
• ISO 13485:2016 quality management system certification, or evidence of equivalent quality management compliance
• Australian Declaration of Conformity, confirming compliance with the TGA's Essential Principles (the Australian equivalent of the EU's Essential Requirements)
• Australian Essential Principles Checklist, documenting compliance with each applicable principle
• Clinical evidence appropriate to the device's risk class: for Class I devices this is typically a clinical evaluation report or literature review; for Class IIa and IIb devices, more substantive clinical data is required
• Risk management documentation consistent with ISO 14971
• Product labelling compliant with TGA labelling requirements: English language, sponsor's name and contact details in Australia, ARTG number once listed
• Instructions for use in English

The TGA's acceptance of CE marking as manufacturer evidence significantly streamlines the ARTG process for Chinese manufacturers who are already exporting to Europe. A Chinese factory with a current CE certificate from a recognised Notified Body, ISO 13485 certification and complete technical documentation is typically in a strong position to support an Australian ARTG application, often without requiring additional testing or audit by the TGA. For more detail on managing this process, see our service page on regulatory compliance.

NDIS and Support at Home Compliance Requirements

Assistive technology funded through the NDIS or the Support at Home AT-HM scheme must meet specific eligibility criteria beyond TGA compliance. Understanding these requirements is essential for aged care providers positioning Chinese-sourced equipment within funded care pathways.

NDIS Assistive Technology Requirements

The NDIS funds assistive technology under Capital Supports where it is reasonable and necessary, directly related to the participant's disability, cost-effective compared to alternatives, and supported by clinical evidence. Equipment exceeding $15,000 requires formal NDIA pre-approval with supporting evidence including a quote and prescription from a suitably qualified health professional.

For NDIS purposes, Chinese-sourced equipment that is correctly ARTG-listed and supported by appropriate clinical evidence is fully eligible for funding. The NDIA's requirement for cost-effectiveness can actively favour Chinese-sourced products: where a TGA-compliant Chinese product delivers equivalent functional outcomes to a European product at lower cost, the NDIA may assess the Chinese product as the appropriate funding choice. The critical requirement is that ARTG listing and clinical evidence are complete and current before the equipment is prescribed and funded.

From mid-2026, the NDIS is transitioning to a new planning framework using the I-CAN v6 assessment tool, which generates budgets algorithmically. For assistive technology, this places greater emphasis on accurate clinical documentation at the initial assessment stage. Providers supplying Chinese-sourced equipment should ensure their clinical partners are familiar with the documentation requirements and that product specifications, ARTG numbers and clinical evidence are readily available to prescribers.

Support at Home and the AT-HM Scheme

Under the Support at Home AT-HM scheme, which launched in November 2025, aged care providers can access separate funding tiers of under $500 (Low), up to $2,000 (Medium) and up to $15,000 or more (High) for assistive technology. The scheme operates on a loan-before-buy principle for eligible items: where a suitable loaned item is not available through the state-based AT Loans scheme, the provider can support the participant to purchase.

Equipment purchased under the AT-HM scheme must be prescribed by a suitably qualified health professional (typically an occupational therapist) and must meet the assessed need. Chinese-sourced equipment that is ARTG-listed, clinically appropriate and cost-effective is fully eligible under the scheme. Providers using Chinese-sourced equipment in AT-HM contexts should maintain clear product documentation, including ARTG numbers, manufacturer specifications, cleaning and maintenance instructions, and warranty terms, to support the provider's obligations under the scheme and the participant's right to ongoing service support.

For questions about structuring your healthcare market entry with Chinese-sourced products across NDIS and aged care funding streams, Sino Partners provides guidance through the full compliance and commercial pathway.

How to Verify a Chinese Aged Care Equipment Supplier

Supplier verification for aged care equipment requires a higher standard of diligence than most product categories. Equipment used in direct care contexts carries patient safety implications, and the cost of a compliance failure, whether a product recall, an adverse event or a failed ARTG audit, extends well beyond the value of the equipment involved.

Factory Audit

A physical factory audit conducted by a qualified third-party inspector is the foundation of supplier verification for aged care equipment. The audit should verify that the factory has genuine manufacturing capability in the relevant product categories, that its quality management system is operational and consistently applied (not merely documented for certification purposes), and that it has demonstrable experience supplying medical device export markets with the same products it is offering to Australian buyers. Key indicators include: a functioning incoming materials inspection process, in-process quality control checkpoints, finished goods testing facilities with calibrated equipment, a complaint handling and non-conformance management system, and documented post-market surveillance processes required under ISO 13485.

ISO 13485 Certification Verification

ISO 13485 certificates must be verified directly with the issuing certification body. Chinese medical device manufacturers are required to hold a quality management certification aligned to GB/T 42061-2022 (the Chinese national standard equivalent to ISO 13485:2016) for Class II and Class III devices sold in the Chinese domestic market. For export-focused manufacturers, ISO 13485 certification is typically issued by an internationally recognised third-party certification body such as BSI, TUV SUD, SGS, Bureau Veritas or an IAF-accredited body. Certificates should be current, cover the relevant product scope, and list the specific manufacturing site being audited. Never rely solely on a certificate copy provided by the supplier without independent verification through the issuing body's public certificate database.

CE Marking Verification

CE certificates for Class IIa and above medical devices are issued by Notified Bodies and are publicly verifiable. The TGA maintains a list of recognised overseas conformity assessment bodies and certificates. Australian sponsors using a CE certificate as manufacturer evidence for ARTG inclusion must confirm that the certificate is current, covers the specific product and manufacturer site in question, and was issued by a Notified Body recognised under the EU Medical Device Regulation (MDR 2017/745) or, for devices still under transition, the Medical Device Directive (MDD 93/42/EEC). The TGA's abridged assessment pathway for CE-marked devices is well-established and is the most efficient route for Chinese manufacturers with European export history.

Reference Verification

Directly speaking with other international buyers, particularly those in Australia, who have placed multiple successful orders with the factory over several years provides the most reliable quality signal available. A manufacturer's track record with similar buyers, including any incidents of non-conformance and how they were managed, reveals the factory's responsiveness, quality consistency and willingness to support post-sale obligations. Sino Partners' supplier identification process includes reference verification as a standard step before any factory is introduced to an aged care client.

Export Certification and NMPA Documentation

From May 2026, China's National Medical Products Administration (NMPA) implemented updated regulations for medical device export sales certificates, establishing two certificate types: Type I (for devices registered in China) and Type II (for unregistered devices where the manufacturer meets GMP standards). These certificates, processed through provincial authorities within 20 working days, provide additional documentation supporting the legitimacy of the manufacturer's export operations. While an NMPA export certificate is not itself a TGA compliance document, its existence confirms that the manufacturer has engaged the Chinese regulatory system, which is a positive indicator of operational maturity.

Common Aged Care Equipment Categories: Price Comparison and TGA Classification

The following table provides indicative pricing comparisons between Chinese direct-source pricing and Australian market pricing for commonly procured aged care equipment categories, along with TGA classification and typical minimum order quantities. Prices are indicative for 2026 and reflect delivered cost to an Australian facility (FOB China plus sea freight plus duty/GST, excluding ARTG compliance costs).

Notes: Prices are indicative only for 2026 and will vary by specification, quantity, supplier and exchange rate. Australian market prices reflect typical distributor retail/wholesale prices for mid-range products. China direct landed prices include sea freight to a major Australian port and import duties (0% for most categories under ChAFTA) but exclude GST, domestic freight and ARTG compliance costs. ARTG compliance is a one-time cost that amortises across all units supplied under the listing. TGA classification should be confirmed for each specific product based on its intended purpose. Minimum order quantities are indicative; lower quantities may be available at premium pricing or through mixed-container consolidation.

The Sourcing Process: Timeline from Brief to Delivered Product

A well-managed aged care equipment sourcing process from China follows a structured sequence. For standard catalogue products where a verified manufacturer with ARTG-listed products already exists, the timeline from initial brief to first delivery is typically 12 to 16 weeks. For new product specifications, new manufacturers or categories requiring fresh ARTG applications, allow 16 to 24 weeks for the first order, with subsequent orders significantly faster once the supplier relationship and compliance pathway are established.

1. Requirements brief and compliance mapping (Weeks 1 to 2)
   Define the equipment specifications, quantities, required TGA classification and ARTG status, NDIS or AT-HM scheme requirements, and any clinical assessment documentation needed. Identify whether existing ARTG-listed Chinese-source products are available, or whether a new ARTG application is required.
2. Supplier identification and verification (Weeks 2 to 4)
   Identify verified Chinese manufacturers against the specifications. Conduct registry verification, ISO 13485 and CE certificate checks, reference verification and factory audit (where a new supplier relationship is being established). Shortlist two to three qualified manufacturers.
3. RFQ in Mandarin, quotation and negotiation (Weeks 3 to 5)
   Issue a detailed Request for Quotation in Mandarin specifying technical requirements, compliance documentation obligations, quantity, delivery timeframe and payment terms. Conduct price negotiation and confirm the selected supplier. Obtain sample units or product documentation for review where required.
4. ARTG application (if required) (Weeks 4 to 12, overlapping)
   For products requiring a new ARTG listing, the application process can be initiated in parallel with production for the first order. Class I self-declared products can be listed within two to four weeks of lodging a complete application. Class IIa and IIb products requiring TGA review typically take six to twelve weeks. For products where an existing ARTG listing is being used, this step is complete before ordering.
5. Order confirmation and production (Weeks 5 to 11)
   Confirm the purchase order, pay the 30% deposit, and monitor production milestones. Coordinate any compliance modifications required for Australian standards and confirm labelling requirements. Production for standard catalogue aged care products typically takes four to six weeks.
6. Pre-shipment inspection (Week 12)
   Independent quality inspector attends the factory to conduct pre-shipment inspection. A full inspection report with photographic evidence is completed within 24 to 48 hours. Non-conformances are communicated to the factory with a remediation deadline. The 70% balance payment is released only on inspection sign-off.
7. Export, sea freight and Australian customs (Weeks 13 to 15)
   Factory prepares export documentation including commercial invoice, packing list, bill of lading, Certificate of Origin (for ChAFTA preference) and compliance certificates. Sea freight transit from major Chinese ports to Australian ports is typically 14 to 22 days. Australian customs and biosecurity clearance takes one to three business days for compliant shipments with correct documentation.
8. Domestic delivery and goods receipt (Week 15 to 16)
   Domestic freight from the port to the facility. Goods receipt inspection on arrival. Any post-arrival non-conformances are communicated to the supplier within the inspection window specified in the contract.

For ongoing procurement of established product lines from a verified supplier, the process from order confirmation to delivery is typically eight to ten weeks, as the verification, ARTG and sample approval steps are already complete. Aged care providers who consolidate their equipment procurement with a small number of verified Chinese suppliers and establish regular order schedules benefit from priority production slots, stable pricing, and the accumulated relationship capital that comes from being a valued repeat customer.

Our pre-shipment inspection service and supplier identification process are both integrated into this timeline as standard components of Sino Partners' aged care equipment sourcing engagements.

Case Study: How a Residential Aged Care Provider Reduced Equipment Costs by 45%

Risks and How to Manage Them

Direct sourcing of aged care equipment from China carries specific risks that are well-understood and manageable with the right processes. Aged care providers considering Chinese sourcing should understand each risk category and the corresponding mitigation before committing to a procurement programme.

Quality Consistency

The primary quality risk in Chinese manufacturing is not initial quality but batch consistency: a factory that produces excellent first-article samples or initial orders may allow quality to drift in subsequent production runs without a systematic inspection regime. For aged care equipment, where product quality has direct implications for resident safety, this risk requires a structured response.

The appropriate mitigation is mandatory pre-shipment inspection on every order, conducted by an independent third-party inspector at the factory. Pre-shipment inspection catches quality deviations before goods are packed and shipped, when remediation is least costly. Payment terms should make the balance payment contingent on inspection sign-off, not on factory self-certification. For high-volume consumable orders such as continence products, a sampling plan based on order size should be specified in the supply agreement.

TGA Compliance Gaps

The risk that equipment arrives in Australia without the correct ARTG listing or with outdated compliance documentation is entirely preventable through proper planning. Every product category must have its TGA classification confirmed and its ARTG status verified before the first order is placed. For new ARTG applications, the timeline must be built into the sourcing plan to ensure the listing is active before the product is supplied to care recipients.

Ongoing maintenance of ARTG listings, including annual fees, post-market surveillance obligations and regulatory reporting for any adverse events, must be understood by the Australian sponsor before assuming the sponsorship role. Sino Partners' regulatory compliance team supports sponsors through the initial ARTG application and ongoing compliance obligations.

Warranty and After-Sales Support in Australia

Warranty claims on Chinese-manufactured medical devices can be challenging to resolve if the warranty terms are not explicitly defined in the supply agreement. A standard 12-month manufacturer's warranty against manufacturing defects, with a defined process for defective parts replacement and remediation, is achievable from reputable Chinese manufacturers but must be negotiated before the order is placed.

The key questions to resolve are: who holds spare parts in Australia for field repairs, what is the agreed remediation timeline for warranty claims, and what is the process for products that cannot be repaired and require replacement. For high-value equipment such as electric nursing beds, powered wheelchairs and patient hoists, the supply agreement should specify a spare parts holding obligation from the Chinese manufacturer and, where practical, the option for the Australian sponsor to hold a strategic spares inventory for common wear items.

Communication and Relationship Management

Language barriers and time zone differences present practical challenges in managing Chinese supplier relationships without Mandarin-speaking capability. Misspecification of requirements, misunderstanding of compliance obligations and delayed resolution of production issues are all more likely where communication relies entirely on English-language written exchanges with Chinese factory personnel whose English competency may not extend to technical or compliance topics.

The solution is Mandarin-speaking professional representation in China: a bilingual intermediary who can conduct all factory communication, specification review, negotiation and issue resolution in Mandarin, with full documentation provided to the Australian client in English. This is the model Sino Partners operates. It eliminates the communication risk entirely and typically results in better pricing, faster resolution of issues and a stronger supplier relationship than self-directed English-language management allows. For guidance on finding Chinese suppliers in the first place, our broader insights series provides useful context.

How Sino Partners Supports Aged Care Providers Through the Full Sourcing Process

Sino Partners is a Sydney-based advisory firm with a Mandarin-speaking team operating across Australia and China. We work with residential aged care operators, home care providers and NDIS service providers to build cost-efficient, TGA-compliant supply chains for aged care equipment sourced from verified Chinese manufacturers.

Our support for aged care equipment sourcing covers every stage of the process outlined in this guide:

• Equipment procurement review: We map your current equipment spend by category, identify the highest-value Chinese sourcing opportunities, and provide a realistic cost and compliance assessment before any commitment is made.
• Supplier identification and factory verification: We shortlist verified Chinese aged care equipment manufacturers from our established network, conduct factory audits and verify all certifications through primary sources. No unverified factory is introduced to a client. See our supplier identification service for more detail.
• TGA compliance pathway: We map the TGA classification for each product, identify appropriate ARTG pathways, and manage the ARTG application process for new listings in partnership with Australian regulatory consultants. Our regulatory compliance service covers the full ARTG compliance process.
• Mandarin RFQ, negotiation and contract: All factory communication, price negotiation and contract drafting is conducted in Mandarin by our China-based team. Supply contracts are bilingual and specifically drafted for aged care equipment, covering warranty terms, spare parts obligations, quality standards and compliance documentation requirements.
• Pre-shipment inspection: Independent quality inspection at the Chinese factory before payment is released and goods are shipped. Every aged care equipment order managed by Sino Partners includes pre-shipment inspection as standard. See our pre-shipment inspection service.
• Ongoing supplier management: For providers establishing regular procurement cycles, we manage the ongoing supplier relationship, monitor compliance documentation currency, coordinate pre-shipment inspection on each order, and provide a single point of contact in Australia for all supply chain management.

The aged care providers who benefit most from working with Sino Partners are those making significant equipment procurement decisions, whether for a new facility opening, a major refurbishment, or an annual equipment renewal programme, where the cost and compliance complexity justifies professional sourcing management. Providers with annual equipment budgets of $150,000 or more across their operations typically find that the cost of Sino Partners' engagement represents a small fraction of the saving achieved on procurement.

Our work spans residential aged care, home care, palliative care and NDIS contexts. We understand the regulatory environment that governs equipment supply in each setting and the compliance obligations that aged care providers carry as Australian sponsors of TGA-listed products.

Published by Sino Partners, Sydney Australia. June 2026. For aged care equipment sourcing enquiries: info@sinopartners.com.au